<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830648</url>
  </required_header>
  <id_info>
    <org_study_id>VBK12</org_study_id>
    <nct_id>NCT00830648</nct_id>
  </id_info>
  <brief_title>Safety of a Second Dose of Biken's Varicella Vaccine</brief_title>
  <official_title>Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to assess and document the safety of a second dose of&#xD;
      Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having&#xD;
      previously received a first dose of Varicella Biken vaccine.&#xD;
&#xD;
      All subjects will receive a second dose of Varicella vaccine (Varicella Biken) at 4 to 6&#xD;
      years of age.&#xD;
&#xD;
      The expected total duration of follow-up (first visit to last visit) for each subject will be&#xD;
      one month.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the safety after administration of Varicella vaccine</measure>
    <time_frame>one month after vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Varicella Virus Vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Varicela Biken</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Aged 4 to 6 years on the day of inclusion.&#xD;
&#xD;
          -  Informed consent form signed by the parent(s) or legal guardian and by an independent&#xD;
             witness.&#xD;
&#xD;
          -  Subject and parent/guardian able to attend all scheduled visits and comply with all&#xD;
             trial procedures.&#xD;
&#xD;
          -  Written documentation of receipt of a first dose of Varicella Biken vaccine more than&#xD;
             3 months before inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical trial investigating a vaccine, drug, medical device,&#xD;
             or a medical procedure in the 4 weeks preceding the trial vaccination.&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period.&#xD;
&#xD;
          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy&#xD;
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,&#xD;
             or long-term systemic corticosteroids therapy.&#xD;
&#xD;
          -  Known systemic hypersensitivity to any of the vaccine components or history of a&#xD;
             life-threatening reaction to the trial vaccine or to a vaccine containing any of the&#xD;
             same substances.&#xD;
&#xD;
          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination;&#xD;
&#xD;
          -  Planned receipt of any vaccine in the 4 weeks following the trial vaccination.&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C&#xD;
             seropositivity.&#xD;
&#xD;
          -  History of varicella infection (confirmed either clinically, serologically or&#xD;
             microbiologically).&#xD;
&#xD;
          -  Previous vaccination against varicella disease with a vaccine different from Varicella&#xD;
             Biken vaccine.&#xD;
&#xD;
          -  Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection&#xD;
             on the day of vaccination, according to investigator judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1406DGI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>varicella-zoster virus</keyword>
  <keyword>varicella</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

